Protocols
1 protocol(s) meet the specified criteria
Drug: TAK-659
Protocol No.TitleStatus
C34005A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (+/- Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of TherapyOpen